The Department of Health has today announced that three new Non-Executive Directors will join the board of the Medicines and Healthcare Products Regulatory Agency (MHRA).
MHRA regulates medicines and medical devices to ensure that they work and are acceptably safe for patients.
The three Non-Executive Directors are:
Dame Valerie Beral, Director of the Cancer Epidemiology Unit at the University of Oxford;
Professor Alexander Markham, Professor of Medicine at the University of Leeds and;
Professor David Webb, Christison Professor of Therapeutics and Clinical Pharmacology at the University of Edinburgh.
MHRA incorporates the Clinical Practice Research Datalink (CPRD), a world-class e-health research service and the National Institute for Biological Standards and Control (NISBC), the world leader in assuring the standards of biological medicines.
Lord Howe, Health Minister, said:
I am pleased to appoint Dame Valerie Beral, Professor Alexander Markham and Professor David Webb as Non-Executive Directors of the MHRA.
They bring a wealth of experience to our board and will play a key role in the leadership of the agency in its vital role, improving and protecting public health.
Sir Gordon Duff, Chairman of the MHRA, said:
I’m delighted that Dame Valerie, Sir Alex and Professor Webb have accepted appointments as Non-Executive Directors of the MHRA. They will bring highly relevant experience and expertise to our board at a time of significant development of the Agency, and will contribute importantly to our strategic leadership.
For media enquiries please ring the Department of Health on 0207 210 5197.
The MHRA is an executive agency of the Department of Health and operates as a government trading fund, generating the majority of its income through fees and charges to the industries it regulates.
The appointments are for three years and will each receive £7,883 per annum for a time commitment of 2 to 3 days per month.
For further information on the MHRA visit their website.